Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA4 | P22748 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2563455 | 1.00 | CTSK (0.47) | CTSKCA2CA4CA9CA1 | |
| SCHEMBL2563452 | 1.00 | CTSK (0.47) | CTSKCA2CA4CA9CA1 | |
| SCHEMBL14955225 | 0.84 | HPGD (0.41) | CTSKCA2CA4CA9CA1 | |
| SCHEMBL14955226 | 0.84 | HPGD (0.41) | CTSKCA2CA4CA9CA1 | |
| SCHEMBL2577682 | 0.83 | CTSK (0.50) | CTSKHPGDTYMP | |
| SCHEMBL2577678 | 0.83 | CTSK (0.50) | CTSKHPGDTYMP | |
| SCHEMBL2577674 | 0.83 | CTSK (0.50) | CTSKHPGDTYMP | |
| SCHEMBL2567895 | 0.83 | NSD3 (0.52) | HPGDNSD3AHCYADORA2ASMN1; SMN2 | |
| SCHEMBL14955424 | 0.83 | NSD3 (0.52) | HPGDNSD3AHCYADORA2ASMN1; SMN2 | |
| SCHEMBL8540429 | 0.75 | TYMP (0.64) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087219-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS INC (US) | 2021-03-25 | — | — | US | disclosed |
| US-10913767-B2 | Oligonucleotides comprising acyclic and abasic nucleosides and analogs | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20130130378-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2011133876-A2 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913767-B2 | Oligonucleotides comprising acyclic and abasic nucleosides and analogs | NSUN2, BCDIN3D, ADAR | CTSK 4410/4885CA2 3603/4885CA4 3247/4885 |
| US-20130130378-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ADAR, TYMS, POLM | CTSK 3939/4885CA2 3740/4885CA4 2779/4885 |
| US-20210087219-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | NSUN2, BCDIN3D, RNGTT | CTSK 4541/4885CA2 3687/4885CA4 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.